SCHEMBL523100

SCHEMBL523100

[CH2]CCc1nnn[nH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29748 0.84
SCHEMBL4671779 0.84
SCHEMBL416692 0.82 L3MBTL1 (0.30)
SCHEMBL6050257 0.82 L3MBTL1 (0.30)
SCHEMBL1127858 0.82 L3MBTL1 (0.30)
SCHEMBL6050352 0.82 L3MBTL1 (0.30)
SCHEMBL2094922 0.82 L3MBTL1 (0.30)
SCHEMBL415693 0.82 L3MBTL1 (0.30)
SCHEMBL1127353 0.82 L3MBTL1 (0.30)
SCHEMBL4714660 0.82 L3MBTL1 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024104425-A1 KRAS INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF 广东东阳光药业股份有限公司 2024-05-23 WO claimed
CN-118047801-A KRAS inhibitor compound, pharmaceutical composition and application thereof 广东东阳光药业股份有限公司 2024-05-17 CN claimed
WO-2024121086-A1 NOVEL COMPOUNDS AS MODULATORS OF NLRP3 INHIBITION F. HOFFMANN-LA ROCHE AG (CH) 2024-06-13 WO disclosed
WO-2024104425-A1 KRAS INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF 广东东阳光药业股份有限公司 2024-05-23 WO disclosed
CN-118047801-A KRAS inhibitor compound, pharmaceutical composition and application thereof 广东东阳光药业股份有限公司 2024-05-17 CN disclosed
US-11213031-B2 Tetrazolylpropyl derivatives and their use as fungicides BAYER AKTIENGESELLSCHAFT (DE) 2022-01-04 US disclosed
US-11213031-B2 Tetrazolylpropyl derivatives and their use as fungicides BAYER AKTIENGESELLSCHAFT (DE) 2022-01-04 US disclosed
US-11213031-B2 Tetrazolylpropyl derivatives and their use as fungicides BAYER AKTIENGESELLSCHAFT (DE) 2022-01-04 US disclosed
EP-2464623-B1 THE RING OPENING OF LACTONES AND LACTAMS NOVARTIS AG (CH) 2020-11-04 EP disclosed
US-20200308109-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC (JP) 2020-10-01 US disclosed
EP-3710432-A1 TETRAZOLYLPROPYL DERIVATIVES AND THEIR USE AS FUNGICIDES Bayer Aktiengesellschaft (DE) 2020-09-23 EP disclosed
WO-1993025205-A1 PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF ANEMIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-12-23 WO disclosed
EP-0561252-A1 2-Oxoquinoline derivatives as angiotensin II antagonists MERCK PATENT GmbH (DE) 1993-09-22 EP disclosed
EP-0546449-A2 Benzofuranderivatives as angiotensin II antagonists MERCK PATENT GmbH (DE) 1993-06-16 EP disclosed
US-5204346-A Cognition activators; analgesics; antidepressants; vasodilation; cardiovascular and urogential disorders; FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-04-20 US disclosed
EP-0505893-A1 Imidazopyridines MERCK PATENT GmbH (DE) 1992-09-30 EP disclosed
EP-0497258-A2 Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-08-05 EP disclosed
US-5089499-A Anticarcinogenic agents; thymidylate synthetase inhibitors; antiallergens; psoriasis IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-02-18 US disclosed
EP-0467248-A2 Pyrazolopyridine compound and processes for preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-01-22 EP disclosed
US-4992544-A Intermediates for b-lactam antibiotics and b-lactamase inhibitor UNIVERSITY OF NOTRE DAME DU LAC (US) 1991-02-12 US disclosed